vTv Therapeutics Inc. (NASDAQ:VTVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $5.50 target price on the stock. Zacks Investment Research’s target price would suggest a potential upside of 10.22% from the stock’s current price.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

VTVT has been the subject of several other reports. HC Wainwright initiated coverage on shares of vTv Therapeutics in a research note on Monday, September 26th. They issued a “buy” rating and a $13.00 target price for the company. Piper Jaffray Cos. restated an “overweight” rating and issued a $24.00 target price on shares of vTv Therapeutics in a research note on Saturday, October 15th. Finally, Canaccord Genuity restated a “buy” rating and issued a $15.00 target price on shares of vTv Therapeutics in a research note on Friday, August 19th. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $15.70.

vTv Therapeutics (NASDAQ:VTVT) opened at 4.99 on Tuesday. The firm has a 50-day moving average price of $6.46 and a 200-day moving average price of $6.00. vTv Therapeutics has a one year low of $4.77 and a one year high of $7.70. The firm’s market capitalization is $48.37 million.

A number of hedge funds have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in vTv Therapeutics by 0.8% in the third quarter. Northern Trust Corp now owns 81,262 shares of the company’s stock valued at $584,000 after buying an additional 622 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in vTv Therapeutics by 0.4% in the third quarter. Ameriprise Financial Inc. now owns 162,080 shares of the company’s stock valued at $1,165,000 after buying an additional 596 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in vTv Therapeutics by 7.6% in the third quarter. Bank of New York Mellon Corp now owns 21,278 shares of the company’s stock valued at $153,000 after buying an additional 1,504 shares in the last quarter. State Street Corp boosted its stake in vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock valued at $488,000 after buying an additional 22,983 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock valued at $559,000 after buying an additional 18,112 shares in the last quarter. 12.84% of the stock is currently owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

5 Day Chart for NASDAQ:VTVT

Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.